However, since both compounds decrease ACE2 and TMPRSS2 expression and ultimately prevent SARS-CoV-2 infectivity in vitro (albeit with different IC50 values), further research is needed to define the precise mechanisms that could account for disparate clinical outcomes in COVID-19 treatment. This evidence concerns the gene TMPRSS2 and COVID-19.